Defective Drugs

Nuplazid (pimavanserin) is a relatively new drug approved to treat patients with Parkinson's disease who suffer delusions, psychosis symptoms and hallucinations. Since it was approved for the market, however, an astonishing number of patients have suffered serious adverse events—including death and life-threatening events—while other patients say they did not obtain the benefits they expected.

We use cookies to give you the best experience on our website. To accept our cookies click Accept. If you choose no, you may still use the site, but experiences can vary.AcceptRevoke CookiesPrivacy policy